北大医药拟购买大新药业9.75%股份

Core Viewpoint - The company plans to acquire a 9.75% stake in Chongqing Daxin Pharmaceutical Co., Ltd. from Southwest Synthetic Pharmaceutical Group through public auction to reduce reliance on leasing and mitigate operational uncertainties [1] Group 1: Strategic Intent - The transaction aims to address the current dependency on leasing for core production assets of Daxin Pharmaceutical [1] - The company intends to engage deeply in the raw material pharmaceutical industry through strategic equity investments [1] - The goal is to enhance the continuity and stability of the production system, ensuring production safety and effective execution of long-term strategies [1] Group 2: Industry Outlook - By deepening collaboration within the upstream supply chain, the company expects to directly benefit from the potential profit increase associated with the positive trends in the raw material pharmaceutical industry [1] - This strategic move is anticipated to optimize the company's overall profitability and achieve a win-win situation within the industry chain [1]